Advertisement
Canada markets closed

  • S&P/TSX

    21,807.37
    +98.93 (+0.46%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CAD/USD

    0.7275
    +0.0012 (+0.16%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • Bitcoin CAD

    87,954.77
    +2,175.04 (+2.54%)
     

  • CMC Crypto 200

    1,371.97
    +59.34 (+4.52%)
     

  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     

  • RUSSELL 2000

    1,947.66
    +4.70 (+0.24%)
     

  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     

  • NASDAQ

    15,282.01
    -319.49 (-2.05%)
     

  • VOLATILITY

    18.71
    +0.71 (+3.94%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6824
    +0.0003 (+0.04%)
     

Today's Research Reports on Canopy Growth, IntelliPharmaCeutics, Aralez Pharmaceuticals and ABcann Global

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / June 29, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI Initiates Coverage on:

Canopy Growth Corporation
https://rdinvesting.com/news/?ticker=WEED.TO

IntelliPharmaCeutics International Inc.
https://rdinvesting.com/news/?ticker=IPCI.TO

Aralez Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=ARZ.TO

ABcann Global Corporation
https://rdinvesting.com/news/?ticker=ABCN.V

ADVERTISEMENT

Canopy Growth's stock jumped 9.69% Thursday, to close the day at $40.51. The stock recorded a trading volume of 10,918,410 shares, which was above its three months average volume of 5,401,279 shares. In the last year, Canopy Growth's shares have traded in a range of 7.73 - 48.72. The share price has gained 424.06% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $37.79 is greater than its 200-day moving average of $31.95. Shares of Canopy Growth have gained approximately 36.21 percent year-to-date.

Access RDI's Canopy Growth Corporation Research Report at:
https://rdinvesting.com/news/?ticker=WEED.TO

On Thursday, shares of IntelliPharmaCeutics recorded a trading volume of 4,000 shares, which was below the three months average volume of 7,293 shares. The stock ended the day 14.29% higher at 0.56. The share price has gained 36.59% from its 52-week low with a 52-week trading range of 0.41 - 3.73. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.55 is below its 200-day moving average of $0.77. Shares of IntelliPharmaCeutics have fallen approximately 43.43 percent year-to-date.

Access RDI's IntelliPharmaCeutics International Inc. Research Report at:
https://rdinvesting.com/news/?ticker=IPCI.TO

Aralez Pharmaceuticals' stock moved 5.10% lower Thursday, to close the day at $0.47. The stock recorded a trading volume of 52,505 shares, which was below its three months average volume of 108,917 shares. In the last year, Aralez Pharmaceuticals' shares have traded in a range of 0.46 - 3.72. The stock is currently trading 87.50% below its 52 week high. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.54 is below its 200-day moving average of $1.66. Shares of Aralez Pharmaceuticals have fallen approximately 74.02 percent year-to-date.

Access RDI's Aralez Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ARZ.TO

On Thursday, shares of ABcann Global recorded a trading volume of 472,616 shares, which was below the three months average volume of 898,748 shares. The stock ended the day 5.38% higher at 1.37. The share price has gained 71.25% from its 52-week low with a 52-week trading range of 0.80 - 4.06. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $1.48 is below its 200-day moving average of $1.90. Shares of ABcann Global have fallen approximately 10.46 percent year-to-date.

Access RDI's ABcann Global Corporation Research Report at:
https://rdinvesting.com/news/?ticker=ABCN.V

Our Actionable Research on Canopy Growth Corporation (TSX:WEED.TO) and IntelliPharmaCeutics International Inc. (TSX:IPCI.TO) and Aralez Pharmaceuticals Inc. (TSX:ARZ.TO) and ABcann Global Corporation (TSXV:ABCN.V) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com